Drug Abuse: Treatment and Management

Substance Abuse Disorders

Volumn , Issue , 2011, Pages 53-74

  Schifano, Fabrizio ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Benzodiazepines; Buprenorphine; Cocaine; Ecstasy; Methadone; Methamphetamine; Naltrexone; Psychosocial treatment; Substance misuse; Treatment

Indexed keywords

EID: 79960353085     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975084.ch3     Document Type: Chapter

References (80)

1. Heidbreder, C.A. and Hagan, J.J. (2005) Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Current Opinion in Pharmacology, 5, 107-118.
2. Corkery, J., Schifano, F., Ghodse, A.H., et al. (2004) Methadone effects and its role in fatalities. Human Psychopharmacology Clinical and Experimental, 19, 565-576.
3. Ghodse, A.H., Schifano, F., Oyefeso, A., et al. (2003) Drug-related deaths as reported by coroners in England, Wales, Scotland, N Ireland and Channel Islands. Annual review 2002 and np-SAD Report no. 11. European Centre for Addiction Studies: London, St George's Hospital Medical School
4. Wolff, K., Rostami-Hodjegan, A., Hay, A.W., et al. (2000). Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction, 95, 1771-1783.
5. Ghodse, A.H., Oyefeso, A.,Webb, L. et al. (2002) Drug-Related Deaths as Reported by Coroners in England and Wales: Annual Review 2001 and np-SAD Surveillance Report no. 9. Centre for Addiction Studies: London, St George's Hospital Medical School.
6. Wu, C. and Henry, J.A. (1990) Deaths of heroin addicts starting on methadone maintenance. The Lancet, 335, 424.
7. Drummer, O.H., Opeskin, K., Syrjanen,M., et al. (1992) Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. American Journal of Forensic Medical Pathology, 13, 346-350.
8. Department of Health: Drug Misuse & Dependence (2007) UK Guidelines on Clinical Management.
9. Hull, C.J. (1985) Receptor binding and its significance. British Journal of Anaesthesia, 57, 131-133.
10. Rosenbaum, J.S., Holford, N.H. and Sadee, W. (1985) In vivo receptor binding of opioid drugs at the mu site. Journal of Pharmacology and Experimental Therapeutics, 233, 735-740.
11. Dum, J., Blasig, J. and Herz A (1981) Buprenorphine: Demonstration of physical dependence liability. European Journal of Psychopharmacology, 70, 293-300.
12. Cowan A., Doxey, J.C. and Harry, E.J.R. (1977) The animal pharmacology of buprenorphine, an oripavine analgesic agent. British Journal of Pharmacology, 60, 647-654.
13. Ghodse, A.H. (1989) Benefit-risk of agonist-antagonist analgesics. British Journal of Addiction, 84, 455-457.
14. Bullingham, R.E.S., McQuay, H.J., Porter, E.J.B. et al. (1982) Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis. British Journal of Clinical Psychopharmacology, 13, 665-673.
15. McQuay, H.J., Moore, R.A. and Bullingham, R.E.S. (1985) Buprenorphine kinetics, in Opioid Analgesics in the Management of Clinical Pain (eds. K. Foley and C. Inturissi), Raven Press, New York.
16. Gilvarry, E. and Schifano, F. (2002) Medical use of buprenorphine in the UK. Special report prepared for the WHO, February 2002, pp. 1-93.
17. Dollery, C. (1999). Buprenorphine hydrochloride. In: Therapeutic Drugs, 2nd edn, Edinburgh: Church Livingstone
18. British Medical Association and Royal Pharmaceutical Society of Great Britain (2008) British National Formulary. London.
19. Ibrahim, R.B., Wilson, J.G., Thorsby, M.E. et al. (2000) Effects of buprenorphine on CYP3A activity in rat and human liver microsomes. Life Sciences, 66, 1293-1298.
20. Johnson, R.E. and McCagh, J.C. (2000) Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports, 2, 519-526.
21. Zacny, J.P., Conley,K. and Galinkin, J. (1997) Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. Pharmacology and Experimental Therapeutics, 282, 1187-1197.
22. Reisine, T. and Pasternak, G. (1995) Opioid analgesics and antagonists, in Goodman & Gilman's ThePharmacologicalBasis of Therapeutics, 9th edn (eds. J.G. Hardmann, A. Goodmann Gilmann and L.E. Limbird), McGraw Hill, New York.
23. Mattick, R.P., Ali, R., White, J. et al. (1999) A randomised double-blind trial of buprenorphine tablets versus methadone syrup for maintenance therapy: efficacy and cost effectiveness. NIDA Research Monograph Series, 180, 77.
24. Ling, W., Charuvastra, C., Collins, J.F. et al. (1998) Buprenorphine maintenance of opiate dependence: a multicenter, randomised clinical trial. Addiction, 93, 475-486.
25. Johnson, R., Jaffe, J. and Fudala, P. (1992) A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association, 267, 2750-2755.
26. Kosten, T., Shottenfeld, R., Ziedonis, D. et al. (1993) Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease, 181, 358-364.
27. Barrau, K., Thirion, X., Micallef, J. et al. (2001) Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction, 96, 1433-1441.
28. West, S., O'Neal, K., Graham, C. (2000) A meta-analysis comparing the effectiveness of buprenorphine and methadone, Journal of Substance Abuse 12: 405-414.
29. San, L., Cami, J., Fernandez, T. et al. (1992) Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. British Journal of Addiction, 87, 55-62.
30. Auriacombe, M., Franques, P., Tignol, J. (2001). Deaths attributable to methadone vs buprenorphine in France. Journal of the American Medical Association, 285: 45
31. Kintz, P. (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Sciences International, 121, 65-69
32. Raynaud, M., Petit, G. and Potard, D. et al. (1998) Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction, 93, 1385-1392.
33. Bouley,M.,Viriot, E., Barache, D. (2000) Practical reflections on the diversion of drugs. Therapie, 55: 295-301
34. Vickers A P, Jolly A (2006) Naltrexone and problems in pain management. British Medical Journal, 332, 132-133.
35. Carreno, J.E., Alvarez, C.E. and San Narciso, G.I. et al. (2003) Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology, 8, 429-438.
36. Foster, J., Brewer, C. and Steele, T. (2003) Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addiction Biology, 8, 211-217.
37. Hulse, G.K., Arnold-Reed, D.E., O'Neil, G. et al. (2004a) Naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addiction Biology, 9, 59-65.
38. Hulse, G.K., Arnold-Reed, D.E., O'Neil, G. et al. (2004b) Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addiction Biology, 9, 67-72. 39. Schifano, F. (1996). Cocaine misuse and dependence. Current Opinion in Psychiatry, 9: 225-30.
39. Schifano, F. (1996). Cocaine misuse and dependence. Current Opinion in Psychiatry, 9: 225-30.
40. Winstock, A. and Schifano, F. (2009) Disorders relating to the use of ecstasy, other 'party drugs' and khat, in New Oxford Textbook of Psychiatry (eds. M. Gelder, N. Andreasen, J.J. Lopez-Ibor and J. Geddes). Oxford University Press, Oxford.
41. Schifano, F. (2005) Substance misuse in the workplace, in Addiction at Work: Tackling Drug Use and Misuse in the Workplace (ed. A.H. Ghodse), Gower Publishing Ltd., London.
42. de Lima, M.S., de Oliveira Soares, B.G., et al. (2002) Pharmacological treatment of cocaine dependence: a systematic review. Addiction, 97, 931-949.
43. Schifano, F. (2009). Stimulant drugs (cocaine; methamphetamine) and recent pharmacological advances in treatment. SCANbites, 1-3.
44. McDowell, D., Nunes, E.V., Seracini, A.M. et al. (2005) Desipramine treatment of cocainedependent patients with depression: a placebo-controlled trial. Drug and Alcohol Dependence, 80, 209-221.
45. Ukai, M. and Mitsunaga, H. (2005) Involvement of dopamine D3 and D4 receptors in the discriminative stimulus properties of cocaine in the rat. Methods and Findings Experimental Clinical Pharmacology, 27, 645-649.
46. Moeller, F.G., Schmitz, J.M., Steinberg, J.L. et al. (2007) Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. American Journal of Drug and Alcohol Abuse, 33, 367-378.
47. Hamilton, J.D., Nguyen, Q.X., Gerber, R.M. et al. (2009) Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. American Journal of Addictions, 18, 48-52.
48. Minozzi, S., Amato, L., Davoli, M. et al. (2008) Anticonvulsants for cocaine dependence. Cochrane Database Systematic Reviews 2 (Art. No. CD006754).
49. Lile, J.A., Stoops,W.W., Allen, T.S. et al. (2004) Baclofen does not alter the reinforcing, subjectrated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology (Berl), 171, 441-449.
50. Sofuoglu, M., Singha, A., Kosten, T.R., et al. (2003) Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacology Biochemistry and Behaviour, 75, 801-808
51. Mooney, M.E., Herin, D.V., Schmitz, J.M. et al. (2009) Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 101, 34-41.
52. McCance-Katz, E., Sevarino, K. et al. (1999) Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges. Nihon Shinkei Seishin Yakurigaku Zasshi 19, 159-186.
53. Reis, A.D., Castro, L.A., Faria, R. et al. (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Revista Brasileira de Psiquiatria, 30, 132-135.
54. Carroll, K.M., Fenton, L.R., Ball, S.A. et al. (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Archives of General Psychiatry, 61, 264-272.
55. Jofre-Bonet, M., Sindelar, J.L., Petrakis, I.L. et al. (2004) Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. Journal of Substance Abuse Treatment, 26, 225-232.
56. Orson, F.M.,Kinsey, B.M., Singh, R.A. et al. (2009)Vaccines for cocaine abuse. HumanVaccines Apr 20 [Epub ahead of print]
57. Schifano, F. and Corkery J (2008) Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in theUK(1990-2004). Journal of Psychopharmacology, 22, 71-79.
58. Schifano, F. (2004) A bitter pill? Overview of ecstasy (MDMA; MDA) related fatalities. Psychopharmacology (Berlin), 173, 242-248.
59. Hindmarch, I. (2005) Medicines in the workplace: the effects of prescribed and OTC drugs on performance, in Addiction at Work: Tackling Drug Use and Misuse in the Workplace (ed. A.H. Ghodse), Gower Publishing Ltd., London.
60. Schifano, F. and Magni, G. (1989) Panic attacks and major depression after discontinuation of long-term diazepam abuse. Drug Intelligence and Clinical Pharmacy; the Annals of Pharmacotherapy, 23, 989-990.
61. Forza, G., Levarta, E., Da Ros, D., et al. (1998) Benzodiazepines consumption in a sample of methadone maintained patients: Characteristics of use and psychopathological profile. European Psychiatry, 13 (4), s15.
62. Waldron, H.B. and Turner, C.W. (2008) Evidence-based psychosocial treatments for adolescent substance abuse. Journal of Clinical Child and Adolescent Psychology, 37, 238-261.
63. Burleson, J.A. and Kaminer, Y. (2005) Self-efficacy as a predictor of treatment outcome in adolescent substance use disorders. Addictive Behaviour, 30, 1751-1764.
64. Liddle, H.A., Dakof, G.A., Turner, R.M. et al. (2008) Treating adolescent drug abuse: a randomized trial comparing multidimensional family therapy and cognitive behavior therapy. Addiction, 103, 1660-1670.
65. Lee, N.K. and Rawson, R.A. (2008) A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and Alcohol Review, 27, 309-317.
66. Baker, A., Lee, N.K., Claire,M. et al. (2005) Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction, 100, 367-378
67. Messina, N., Farabee, D., Rawson, R. (2003) Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions. Journal of Consulting and Clinical Psychology, 71, 320-329.
68. Epstein, D.H., Schmittner, J., Umbricht, A., et al. (2009) Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence, 101, 92-100.
69. Knapp, W.P., Soares, B.G., Farrell, M. et al. (2007) Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Systematic Reviews, 18, CD003023.
70. Bradley, A.C., Baker, A., Lewin, T.J. (2007) Group intervention for coexisting psychosis and substance use disorders in rural Australia: outcomes over 3 years. Australian New Zealand Journal of Psychiatry, 41, 501-508.
71. Baker, A., Bucci, S., Lewin, T.J. et al. (2006) Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. British Journal of Psychiatry, 188, 439-448.
72. Dutra, L., Stathopoulou, G., Basden, S.L., et al. (2008) A meta-analytic review of psychosocial interventions for substance use disorders. American Journal of Psychiatry, 165, 179- 187.
73. Carroll, K.M., Ball, S.A., Martino, S., et al. (2008) Computer-assisted delivery of cognitivebehavioral therapy for addiction: a randomized trial of CBT4CBT. American Journal of Psychiatry, 165, 881-888.
74. Kadden, R.M., Litt, M.D., Kabela-Cormier, E. et al. (2007) Abstinence rates following behavioral treatments for marijuana dependence. Addictive Behavior, 32, 1220-1236.
75. Walter, M. andWiesbeck, G.A. (2009) Pharmacotherapy of substance dependence and withdrawal syndromes. Therapeutische Umschau, 66, 449-457.
76. Schifano, F., Corkery, J., Gilvarry, E. et al. (2005). Buprenorphine mortality, seizures and prescription data in the UK (1980-2002). Human Psychopharmacology: Clinical and Experimental, 20: 343-348.
77. Schifano, F. (1998) Cocaine misuse and dependence. Current Opinion in Psychiatry, 9, 225-230.
78. Parolaro, D., Rubino, T. (2008) The role of the endogenous cannabinoid system in drug addiction. Drug News and Perspectives, 21, 149-157.
79. Shields A.E. and Lerman, C. (2008) Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clinical Pharmacology and Therapeutics 83, 635-639.
80. Denis, C., Lavie, E., Fatśeas,M., et al. (2006). Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database System Review, 19; 3: CD005336